Disease-Specific Indexes
Poliwogg publishes and licenses disease-specific indexes (the “Poliwogg Indexes”), which are designed to underlie financial instruments such as swaps, forward and futures contracts, options, exchange traded funds, and other structured products. Each individual Index is published monthly, and tracks the average cost per patient in the US of a particular disease or condition for the preceding twelve months. The source data for the Indexes is comprehensive and unique paid claims data.
Bringing together informed analysis and big data, Poliwogg delivers innovative and proprietary indexes that enhance and complete the spectrum of sector based investment and hedging tools.
Poliwogg believes that better price discovery will allow for better transfer and mitigation of risk, with the potential to improve the efficiency of the entire sector.
The first disease-specific Poliwogg Index tracks Type 2 Diabetes, and represents the cost of treating one patient for one year suffering from Type 2 Diabetes. Additional Index releases covering different maladies will occur throughout 2017.
Poliwogg Equity Indexes
Poliwogg applies metrics specific to biotechnology and pharmaceuticals that are not applicable to other sectors or industries, resulting in highly idiosyncratic performance characteristics. Indexes are comprised of companies that are principally engaged in the US health care sector, with a strong emphasis on the dynamic small/mid-capitalization biotechnology segment.
-Poliwogg Medical Breakthroughs Index (TICKER: PMBI)
PMBI has been Licensed ALPS and is the basis for The ALPS Medical Breakthroughs Exchange Traded Fund
-Poliwogg Healthcare Innovation Index (TICKER: PHIX)
PHIX has been licensed to SmartTrust® as the basis for the SmartTrust Healthcare Innovations Unit Investment Trust
-Poliwogg Biopharma Merger & Acquisition Index (TICKER: PBMA)
Poliwogg publishes and licenses disease-specific indexes (the “Poliwogg Indexes”), which are designed to underlie financial instruments such as swaps, forward and futures contracts, options, exchange traded funds, and other structured products. Each individual Index is published monthly, and tracks the average cost per patient in the US of a particular disease or condition for the preceding twelve months. The source data for the Indexes is comprehensive and unique paid claims data.
Bringing together informed analysis and big data, Poliwogg delivers innovative and proprietary indexes that enhance and complete the spectrum of sector based investment and hedging tools.
Poliwogg believes that better price discovery will allow for better transfer and mitigation of risk, with the potential to improve the efficiency of the entire sector.
The first disease-specific Poliwogg Index tracks Type 2 Diabetes, and represents the cost of treating one patient for one year suffering from Type 2 Diabetes. Additional Index releases covering different maladies will occur throughout 2017.
Poliwogg Equity Indexes
Poliwogg applies metrics specific to biotechnology and pharmaceuticals that are not applicable to other sectors or industries, resulting in highly idiosyncratic performance characteristics. Indexes are comprised of companies that are principally engaged in the US health care sector, with a strong emphasis on the dynamic small/mid-capitalization biotechnology segment.
-Poliwogg Medical Breakthroughs Index (TICKER: PMBI)
PMBI has been Licensed ALPS and is the basis for The ALPS Medical Breakthroughs Exchange Traded Fund
-Poliwogg Healthcare Innovation Index (TICKER: PHIX)
PHIX has been licensed to SmartTrust® as the basis for the SmartTrust Healthcare Innovations Unit Investment Trust
-Poliwogg Biopharma Merger & Acquisition Index (TICKER: PBMA)
Location: United States, New York
Phone: +1 855-753-6484
Investors 1
| Date | Name | Website |
| - | Structure ... | structure.... |
Mentions in press and media 10
| Date | Title | Description |
| 31.03.2015 | What the ‘IPO lite’ SEC rule change means for life sciences startups, crowdfunding and venture capital | The standard route would be to hit up venture capital or a handful high net-worth individuals. But new SEC rules under the JOBS Act – dubbed “IPO Lite” and released March 25- now allow startups to get investment from these active, passionat... |
| 09.02.2015 | Cell Therapy may have just raised $1M, but will crowdfunding have a lasting place in biotech? | “It was very fast and very efficient,” Reginald told Reuters. “We have spent 5 percent of our time on fundraising, which enables me to spend 95 percent of my time on the business.” Crowdfunding is increasingly becoming an option for early s... |
| 30.01.2014 | Eager to “democratize” healthcare investing, Poliwogg gives the crowd new ways to join in | So much of the investing power today lies in the hands of elite venture capital and private equity firms, which by the way have progressively shied away from life science investments over recent years. Poliwogg is hoping to fill that fundin... |
| 13.01.2014 | Epilepsy meets the crowd with healthcare crowdfunder Poliwogg | Warren Lammert, chairman of the Epilepsy Foundation’s board of directors and the co-founder of the Epilepsy Therapy Project, said crowdfunding is a “natural follow-on to support young companies” beyond the grants and other support the organ... |
| 30.04.2013 | Converts, cash in short supply to support crowdfunding for medical device companies (video) | “I don’t see how that works in devices–I don’t see one way it works,” he told the audience. It may be great in other sectors, such as consumer electronics, Anderson said. “But what are we going to give people–a medical device?” That doesn’t... |
| - | What the ‘IPO lite’ SEC rule change means for life sciences startups, crowdfunding and venture capital | A new SEC rule change will allow startups to crowdfund for much, much larger sums of money. What does this mean for the life sciences industry? Consider this scenario: You’re an early stage biotech, in an orphan field that has an active and... |
| - | Converts, cash in short supply to support crowdfunding for medical device companies (video) | The medical device sector is ravenous for fresh capital. But they’re not desperate enough to trust crowdfunding. That was confirmed at this week’s 10x Medical Device Conference in Minneapolis, Minnesota, during a panel on new sources for ca... |
| - | Eager to “democratize” healthcare investing, Poliwogg gives the crowd new ways to join in | Greg Simon has a very straight-forward answer to the question of what problem his new company, Poliwogg, is solving: “Underinvestment in healthcare. “And we’re solving it by letting more people have the opportunity to invest in individual c... |
| - | Epilepsy meets the crowd with healthcare crowdfunder Poliwogg | New epilepsy treatments plus solutions for certain genetic liver and lung ailments will test the power of crowdfunding. New York’s Poliwogg will announce today at the JP Morgan Healthcare Conference that it has struck partnerships with the ... |
| - | Cell Therapy may have just raised $1M, but will crowdfunding have a lasting place in biotech? | Biotechs may be flush with cash, thanks to the ol’ bullish IPO market and an uptick in venture funding. But startups remain on the lookout for alternative funding models – with crowdsourcing front and center. This makes British biotech star... |